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Abstract: Polymeric nanoparticles can be used for drug delivery systems in healthcare. For this
purpose poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) offer an excellent
polymeric matrix. In this work, PLGA and PEG polymers were functionalized with coumarin and
carbohydrate moieties such as thymidine, glucose, galactose, and mannose that have high biological
specificities. Using a single oil in water emulsion methodology, functionalized PLGA nanoparticles
were prepared having a smooth surface and sizes ranging between 114–289 nm, a low polydispersity
index and a zeta potential from−28.2 to−56.0 mV. However, for the corresponding PEG derivatives the
polymers obtained were produced in the form of films due to the small size of the hydrophobic core.
Keywords: PLGA; PEG; polymeric nanoparticles; glucose; galactose; thymidine; mannose; coumarins;
drug delivery systems
1. Introduction
Described as the manipulation of atomic matter, nanotechnology was described theoretically in
the 1960s by Richard Feynman, and the practice emerged a decade later. After Taniguchi’s, Drexler’s,
and other scientist’s valuable contributions, nanomedicine has developed [1,2] and recently, the three
main applications of nanomedicine are in tissue engineering, nanoprobes, and nanoparticles for
drug delivery.
Suitable nanoparticles are capable of transporting drugs in a targeted manner to a specific
tissue, cell or organ, minimizing the toxic effects and high therapeutic doses inherent in most
current pharmacological treatments [3–5]. Recent advances in drug encapsulation and/or delivery
of nanoparticles have demonstrated the enormous potential that these nanomaterials can have in
healthcare, and their ability to improve the pharmacokinetic and pharmacodynamic properties of
an active ingredient, thereby increasing the effectiveness of treatment and reducing the toxicity to
patients [6].
Depending on the application (diagnosis, imaging, or therapy), different types of nanoparticles
have been proposed, and these can be divided into two main groups: organic and inorganic
nanoparticles. In the first group are dendrimers, liposomes, and polymeric nanoparticles. The second
group includes quantum dots, silica, gold, and silver nanoparticles. Due to the high rate of tissue
accumulation, that can result in toxicity problems, nanoparticles that cannot be degraded by the
body are not as popular and attractive as biodegradable and biocompatible polymeric nanoparticles
(PNPs) [7,8].
PNPs play an important role in therapeutic applications, such as encapsulation and controlled
drug release [9,10]. The PNP matrix, size [11–13], surface area [14], shape [15,16], and surface electrical
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potential [17–20] are important to circumvent the limitations inherent in drug delivery and must be
appropriate for the intended application.
Targeted drug delivery, also known as “magic bullet”, is a scientific concept proposed by Paul
Ehrlich in 1900, and is the ability to selectively eliminate pathogenic microorganisms without harming
the patient themselves, intending that the drug only acts on its intended target. Unlike most currently
available treatments, PNPs capable of targeting drug delivery to a particular tissue, cell or organ can
be achieved if the surface of the PNP is functionalized accordingly (derivatization with antibodies
or their modified fragments, proteins, peptides, oligonucleotides, or carbohydrates) [19–21]. Highly
specific interactions occur between these ligands and certain receptors of different cell types. Lectins,
for example, present in different organs such as liver cells or over-expressed on the membrane surface
of cancer cells, are able to specifically internalize monosaccharide molecules such as lactose, glucose,
galactose, mannose, amongst others, suggesting the ability to target or accumulate PNPs in these types
of lectin-containing cells [21,22].
With all of this in mind, we have attempted to functionalize commercial polymers, namely
poly(ethylene glycol) (PEG) and poly(lactic-co-glycolic acid) (PLGA), in order to obtain drug delivery
agents, either pro-drugs or nanoparticles for drug encapsulation. Monosaccharides (glucose, galactose,
mannose, and thymidine) were bonded to these polymers to allow specific interactions between
cell receptors and drug delivery agents. Coumarins were also included to potentially increase the
pharmaceutical activity of these polymers, since they are known for their biological properties [23–26],
but also to exploit their use as traceable probes due to their fluorescence character. In some cases, the
click chemistry methodology [27] was used to establish the covalent bonds between these building
blocks. More information about the formation of triazole rings with polymers can be read in an
extensive review written by Arslan and co-workers [28], and in a complete review of polymeric
scaffolds for tissue engineering, written by Zou and co-workers [29].
2. Results and Discussion
Our synthetic strategy began with the preparation of ligands that would be bonded to poly(ethylene
glycol) (PEG) and poly(lactic-co-glycolic acid) (PLGA) polymers. We wanted these bonds to be strong,
but also easily formed, and both 1,2,3-triazole ring and amide linkages present those features, whereby
coumarins, carbohydrates and the polymers were modified accordingly, as described below.
2.1. Ligand Synthesis and Preparation—Coumarins
Coumarins can be obtained commercially or synthesized either by Pechmann condensation [30],
Knoevenagel condensation [31], Perkin reaction [32], or Reformatsky reaction [33], the first two methods
being the most widely used. For this work, however, only one coumarin was synthesized. Pechmann
reaction between 2-methylresorcinol and diethyl-2-acetylglutarate in acidic media afforded 1 in 60%
yield (Scheme 1).
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Scheme 1. Pechmman condensation between 2-methylresorcinol and diethyl-2-acetylglutarate affording
coumarin 1.
Propargylation reactions of 1, and other commercially available coumarins, namely umbelliferone,
3-carboxylic acid coumarin, and 4-methyl-7-hydroxy coumarin, are presented in Scheme 2.
The propargylation conditions used were the ones already reported in the literature [34,35]. Alkyne
coumarins 2, 4, 5, and 6 were obtained in excellent yields, and pure enough for further reactions.
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NMR and FT-IR spectra (see Supplementary Materials for 1H, 13C and MS/MALDI-TOF spectra for
novel synthesized compounds) were in accordance with those already reported in the literature.
For propargylated coumarin 4, methylene protons were observed at 4.77 ppm, and the alkyne proton
at 2.58 ppm. Alkyne stretch bands were observed at 3266 and 2119 cm−1. Coumarin 5 presented the
methylene proton signal at 4.95 ppm and the alkyne proton at 2.56 ppm. FT-IR spectrum presented
the alkyne stretches at 3315 and 2117 cm−1. Ester hydrolysis of 2 was accomplished with sodium
hydroxide in ethanol at 80 ◦C, affording 3 in 95% yield.
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Sche e 2. Propargylation of 1, u belliferone, 3-carboxylic acid, and 4- ethyl-7-hydroxy cou arin,
affording the corresponding alkynes. Reaction conditions for ester for ation: i) propargyl alcohol,
, -dicyclohexylcarbodii ide (DCC), 4-di ethyla inepyridine (D P), C Cl (DC ), 18 h.
Conditions for ether for ation, and ii) propargyl bromide, KI, K2CO3, dimethylfor amide (DMF),
80 ◦C, 2 h 30 min.
In some cases, a linker was necessary in order to bond the coumarin, or the carbohydrate, moiety
to the polymer and for these cases compound 7 was prepared. Due to its high volatility and reactivity,
7 was always maintained in diethyl ether, even for its quantification and characterization. Subsequent
triazole ring formation with coumarin 6, afforded 8 in good yield (Scheme 3).
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Sche e 3. Triazole linker 8 as prepared by the substitution of bro ide in 2-bro oethyla ine
hydrobro ide using sodiu azide, follo ed by cycloaddition to for the 1,2,3-triazole ring.
2.2. Ligand Preparations Carbohydrates
Specific carbohydrate derivatization was challenging due to the presence of several hydroxyl
groups having si ilar reactivities. However, depending on the reaction conditions, the ano eric
hydroxyl can be preferential replaced. Furthermore, in order for a carbohydrate to be recognized by
lectins, it often must be non-reducing.
Insertion of a triazole ring between the carbohydrate moiety and the coumarin/polymer moieties
not only increases the linkage strength, but i ics the a ide group, which can induce, or i prove,
the biological activity of the final co pounds. Propargylation of glucose, galactose, and annose
(Sche e 4) using i obilized sulfuric acid on silica [36], afforded the necessary terminal alkynes,
9–11, for posterior cycloaddition reactions. The propargylation yields obtained were poor to oderate
(38%–68%), and the products were ixtures of α and β ano ers, with a 2:1 ratio. This ratio was
calculated taking advantage of the vicinal coupling constants characteristics for hexoses (α proton
near 5 pp as a broad singlet and β proton around 4.50 ppm, with 3J 1–H2 = 7.9 Hz), and with 1JH-C
coupling constant for annopyranose 11. Benzylation of α and β propargyl glucopyranosyl ixtures
afforded the per-O-benzylated anomers, which could be separated by column chromatography, using
6:1 hexane/ethyl acetate as eluent.
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Acetylation of propargyl glucopyranose 9, afforded 12. Subsequent triazole formation with azide
7 afforded 13 in good yield. De-acetylation using sodium methoxide led to the corresponding product
14 (Scheme 5).
olecules 2020, 25, x FOR PEER REVIE  4 of 21 
 
 
Sche e 4. Propargylation reaction of D-glucose, D-galactose, and D- annose using sulfuric acid 
i obilized on silica, affording the alkynes 9, 10, and 11, respectively. 
cetylation of propargyl glucopyranose 9, afforded 12. Subsequent triazole for ation ith 
azide 7 afforded 13 in good yield. e-acetylation using sodiu  ethoxide led to the corresponding 
product 14 (Sche e 5). 
 
Sche e 5. Preparation of glycosyl a ine 14 fro  propargyl glucoside 9. 
2.3. Ligand Preparations Thy idine 
Tosylation of the pri ary hydroxyl group of 2’-deoxythy idine as acco plished using tosyl 
chloride (15, Sche e 6). Subsequent reaction ith sodiu  azide, either by conventional heating in 
di ethylfor a ide ( F) using an oil bath (85 °C, 15 h, 87 ), or using icro ave irradiation (100 
°C, 250 , 2 in, 90 ), afforded the corresponding azide 16. lthough a yield i prove ent as not 
significant using icro ave heating, the reaction ti e as drastically reduced. 
 
Sche e 6. Synthesis of thy idine azide 16 by regioselective tosylation, follo ed by azide 
substitution, either using icro ave or conventional heating. 
aving the ligands already prepared, they ere used to prepare PE  and PL  derivatives, as 
described in the follo ing sections. 
2.4. PEG erivatives 
PE  is a versatile poly er for pro-drug develop ent due to its high solubility in ater and 
available co ercially at various olecular eights, and its stealth properties [37]. PE  pro-drugs 
often di inish collateral effects and can be specifically ad inistered on targeted tissues [38]. 
lthough the conjugation of phar aceutical agents ith PE  has brought significant i prove ents 
such as an increased solubility in ater, prolonged liberation rates, and reduction of toxicity, 
proble s such as the necessity for high doses and drug resistance are still a aiting resolution. ulti-
c e e 5. Preparation of glycosyl a i e 14 fr r ar l l c si e 9.
2.3. Ligand Preparations—Thymidine
Tosylation of the primary hydroxyl group of 2’-deoxythymidine was accomplished using tosyl
chloride (15, Scheme 6). Subsequent reaction with sodium azide, either by conventional heating in
dimethylformamide (DMF) using an oil bath (85 ◦C, 15 h, 87%), or using microwave irradiation (100 ◦C,
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Having the ligands already prepared, they were used to prepare PEG and PLGA derivatives, as
described in the following sections.
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2.4. PEG Derivatives
PEG is a versatile polymer for pro-drug development due to its high solubility in water and
available commercially at various molecular weights, and its st alth properties [37]. PEG pro-drugs
often diminish collateral effects and can be specifically administered on targ ted tissues [38]. Altho h
the conjugation of pharmaceutical gents with PEG has brought significant improv ments ch as an
increased solubility in water, prolong d liberation rates, and reduction of toxicity, problems such a
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the necessity for high doses and drug resistance are still awaiting resolution. Multi-therapy presents
itself as a viable solution since polymeric pro-drugs are able to form nanoparticles that are able to
encapsulate a different drug, allowing the reduction of administered doses, and consequently an
increased therapeutic efficiency [39–41].
Esterification of coumarin 3-carboxylic acid with PEG using N,N-dicyclohexylcarbodiimide (DCC),
and catalytic 4-dimethylaminepyridine (DMAP, Scheme 7) afforded the fluorescent polymer 17 in
excellent yield. Product formation was observed by FT-IR, which confirmed the presence of the ester
linkage at 1766 cm−1. The proton NMR spectrum showed the presence of one coumarin moiety,
determined by comparing the relative intensity of the coumarin signals to PEG signals, since PEG
with an average molecular weight of 1000 g/mol was expected to present between 84 and 96 protons.
Integration of aromatic signals between 8.57 and 7.32 ppm for one coumarin, resulted in 88 PEG
protons (between 4.60 and 3.50 ppm), which is within the expected values. This is a very important
result, since the other PEG hydroxyl should be free to link to the carbohydrate moiety. A 13C NMR
spectrum supports the esterification success through coumarin signals between 117 and 163 ppm.
The terminal hydroxyl of ester 17 was then tosylated to provide ester 18, in good yield. A tolyl methyl
proton signal was observed at 2.45 ppm and a corresponding carbon signal at 21.6 ppm. Aromatic
proton signals where observed between 7.90 and 7.32 ppm, and between 136.5 and 115.5 ppm in
the carbon spectrum. The tosyl group was substituted using sodium azide in DMF, affording the
azide 19 in very good yield. Product formation was confirmed by the absence of tosyl signals both
in the proton and carbon spectra, and by the observation of an azide stretch band in the FT-IR at
2104 cm−1. Cycloaddition with the previously prepared propargyl galactopyranose 10 using catalytic
CuI, and diisopropylethylamine (DIPEA) in freshly distilled tetrahydrofuran (THF) afforded the
desired triazole-containing glycoconjugate 20 in only 18% yield. The poor yield obtained is believed
to be due to copper complexation with the free hydroxyls of propargyl galactopyranose. Adding
2,2’-bipyridyl in excess to the reaction mixture, did not improve this result [42]. A Proton NMR
spectrum showed the triazole proton signals shifted between 8.23 and 7.99 ppm, and the coumarin
signals in the expected aromatic region, namely between 8.60 and 7.30 ppm. Galactopyranose signals
were observed between 5.10 and 4.40 ppm, with PEG signals between 4.30 and 3.34 ppm. Carbon
spectrum confirmed these results, mainly by the presence of the anomeric carbon at 98.8 ppm and
triazole signal at 124.9 ppm. Matrix-Assisted Laser Desorption/Ionization with Time-of-Flight analyser
(MALDI-TOF) mass spectrum presented a medium mass/charge of 1512, where the expected value was
1401 m/z., which result is within the range for (C2H4O)nH2O, with n = 21–24.
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sodium azide reaction with ditosylate 21 (Scheme 8). Formation of di-tosylated product 21 was 
confirmed by proton NMR, where the relative intensity of the tosyl signals, compared to the PEG 
methylene signals, were as expected for the di-tosylation. As such, eight protons appear between 7.90 
and 7.30 ppm corresponding to both tosyl groups. The two corresponding methyl protons presented 
as a singlet at 2.45 ppm. Compound 22 was confirmed by the absence of tosyl NMR signals, and the 
presence of a triplet at 3.39 ppm, corresponding to both methylene groups bonded to azide groups.  
Equimolar cycloaddition of 22 with previously prepared propargyl coumarin 4 afforded 23 with 
very good yields. Proton spectrum presented in the aromatic region the protons belonging to the 
coumarin (between 7.70 and 6.20 ppm) and the triazole (8.00 ppm) moieties. The methylene of the 
coumarin moiety was observed at 5.29 ppm as a singlet, as expected. PEG proton signals were shifted 
in four different places, where the most deshielded triplet, at 4.60 ppm, corresponded to the 
Sche e 7. Synthesis of glycoconjugate 20.
In order to form symmetric or asymmetric PEG derivatives diazide 22 was prepared through
the sodium azide reaction with ditosylate 21 (Scheme 8). Formation of di-tosylated product 21 was
confirmed by proton NMR, where the relative intensity of the tosyl signals, compared to the PEG
methylene signals, were as expected for the di-tosylation. As such, eight protons appear between 7.90
and 7.30 ppm corresponding to both tosyl groups. The two corresponding methyl protons presented
as a singlet at 2.45 ppm. Compound 22 was confirmed by the absence of tosyl NMR signals, and the
presence of a triplet at 3.39 ppm, corresponding to both methylene groups bonded to azide groups.
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Scheme 8. Synthesis of glycoconjugates 24 and 25 from poly(ethylene glycol) (PEG).
Equimolar cycloaddition of 22 with previously prepared propargyl coumarin 4 afforded 23 with
very good yields. Proton spectrum presented in the aromatic region the protons belonging to the
coumarin (between 7.70 and 6.20 ppm) and the triazole (8.00 ppm) moieties. The methylene of the
coumarin moiety was observed at 5.29 ppm as a singlet, as expected. PEG proton signals were shifted
in four different places, where the most deshielded triplet, at 4.60 ppm, corresponded to the methylene
bonded to the triazole moiety, and the more shielded one, at 3.39 ppm corresponded to the methylene
bonded to the azide moiety. Carbon spectrum sustained these results. FT-IR spectrum showed the
azide band at 2106 cm−1, indicating that unwanted di-cycloaddition was not obtained.
Subsequent cycloaddition on the other side of the polymer, either using propargylated
galactopyranose 10 or propargylated mannopyranose 11, led to the formation of glycoconjugates 24 or
25, respectively, in 11% and 17% yields. Structure confirmation by proton NMR was difficult due to the
overlap of PEG and carbohydrate signals, while MALDI results were in accordance with the expected
estimated values (estimated medium value of 1426 m/z, obtained 1511 m/z for compound 24, and 1477
m/z for compound 25).
Diesterification of PEG with coumarin alkyne 3 using DCC afforded a new fluorescent polymer, 26
(Scheme 9). Product 26 was easily identified by proton NMR, where the relative intensity of coumarin
signals, compared to PEG methylene signals, were as expected for the diester. As such, 4 aromatic
protons at 7.47 and 6.98 ppm corresponded to both coumarins. PEG proton signals were identified
at 4.23 and 3.66 ppm, with a relative intensity for 86 protons. Carbon spectrum analysis was also
consistent with the proposed structure (see experimental part).
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Scheme 9. Synthesis of a double thymidine-containing fluorescent PEG derivative, 27, starting by PEG
di-esterification with coumarin 3, followed by double triazole ring formation with thymidine derivative 16.
Subsequent double azide-alkyne Huisgen cycloaddition with thymidine azide 16 using a catalytic
amount of CuI and DIPEA in THF, afforded the symmetric polymer 27. Structural characterization
was observed to be in agreement with the proposed structure. More precisely, proton NMR spectrum
showed new triazole protons at 7.77 ppm and coumarin signals in the expected aromatic region at 7.41
and 6.98 ppm. Thymidine signals were ob erved at 7.30, 6.24, and 4.47 pp , and PEG signals at 4.20
and 3.60 ppm. All the relative intensity for the assigned protons were in agreement with bis-thymidine
cycloaddition. The carbon spectrum confirmed these results, mainly by the presence of a triazole
signal at 135.5 ppm, the anomeric carbon at 84.9 ppm and the PEG main carbon chain at 70.5 ppm.
Molecules 2020, 25, 1744 7 of 21
The MALDI-TOF expected medium value was 2132 m/z, and it was obtained 2153 m/z for compound
27, with sizes ranging from 1932 to 2461 m/z, in which the increment observed was due to ethylene
glycol monomer.
2.5. PLGA Derivatives
PLGA is a hydrophobic, linear and biocompatible polymer, approved by the FDA and EMA for
biological applications [43]. Upon hydrolysis, PLGA is able to release pharmaceutical agents, and the
resulting lactic and glycolic acids are metabolized on the Krebs cycle [44]. A polymer with a molecular
weight range between 7000 and 17,000 g/mol was chosen with a 50:50 glycolic/lactic acid ratio, which
translates into a more amorphous final structure.
PLGA glycoconjugate 28 was prepared by amide formation between 14 and PLGA using
methanesulfonic acid (Scheme 10). Due to the fact that amines are more reactive than alcohols,
it was assumed that an amide was the major product of this reaction, although esterification may have
also occurred.
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Scheme 10. Amidation reaction between poly(lactic-co-glycolic acid) (PLGA) and previously prepared
glycoside 14 to afford the PLGA glycoconjugate 28.
Coumarin 8 reacted with PLGA in the presence of methanesulfonic acid (Scheme 11) to afford the
fluorescent amide, 29.
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Scheme 11. Synthesis of fluorescent PLGA derivative, 29 by direct PLGA amidation with coumarin 8
in acidic conditions.
Proton NMR analysis of compound 28 identified the methyl, methylene, and methine groups
that fo m the polymer at 1.58, 4.83, and 5.22 ppm, respectiv ly. The c aracteristic signal from the
tri zole oiety can be identified at 7.01 ppm, and a few sugar signals betwe n 4.43 and 4.11 ppm.
For poly er 29 it was also possible to identify the methyl, methylene, and methine groups fro the
l r chain at 1.58, 4.83, and 5.24 ppm, respectiv ly, plus the coum rin and triazole characteristic
rotons at 8.29, 7.80, and 7.54 ppm. Identification of these ligands was very difficult, due to high
NMR signal accumulation from the polymer structure. Nevertheles , it was poss ble to identify very
distinct ve signals for both polymers. MALDI-TOF analysis could not be m de for th se polymers due
to their very high polydispersity. Co relation between zeta potentials of th ir respective nanoparticl s,
and these observed NMR signals allowed us to conclude that the functi naliz tion had occurred.
2.6. Nanoparticles Preparation and Characterization
Polymeric glycoconjugates were transformed into nanoparticles with the glycosides towards their
exterior. Oil in water emulsification/solvent evaporation technique is an easy and highly reproducible
method for nanoparticle preparation, and it was our choice for the transformation of the prepared
polymers into nanoparticles.
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Nanoparticles from glycoconjugate 20 were prepared and analyzed by Scanning Electron
Microscopy (SEM) and the results are presented in Figure 1A,B. This glycoconjugate formed mostly
a polymeric film upon deposition, with some dispersed agglomerates. The size of the agglomerates
ranged between 220 and 580 nm.
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Figure 1. Scanning Electron Microscopy (SEM) micrographs of PEG derivatives after oil-in-water
emulsification method to form nanoparticles. (A,B) correspond to galactoconjugate 20; (C,D) correspond
to galactoconjugate 24; and (E,F) account for mannoconjugate 25. Left images have a magnification of
20,000 times, with the bar corresponding to 1 µm, with the exception of (A), where magnification is
10,000 times. Right images have a magnification of 40,000 times, with the bar corresponding to 100 nm.
Glycoconjugates 24 and 25 were also transformed into nanoparticles and analyzed by SEM, and
are presented in Figure 1C–F. Galactoconjugate 24 formed more agglomerates than glycoconjugate
20, and a film was still present. For the mannoconjugate 25, it was observed that it formed irregular
films, with multiple cracks, and a high degree of convolution of neighboring agglomerates either by
the polymer’s preferential formation of films, or due to film deposition on top of those agglomerates.
Dynamic Light Scattering (DLS) technique (results presented in Figure 2), where the particles are
suspended in water in a colloidal manner, showed average particle size of 253 (20), 118 (24), and 193 nm
(25), peak size of 219 (20), 105 (24), and 171 nm (25) and high polydispersity indexes of 5.828 (20),
0.440 (24), and 0.682 (25). These results confirmed that PEG derivatives formed polydisperse samples,
with aggregates.
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PLGA glucoconjugate 28 was capable of forming spherical nanoparticles, with a smooth surface 
and with practically no aggregation as seen in Figure 3 (A) and (B). The particles presented a size 
range of 114–234 nm. DLS gave similar results, with an average particle size of 189 nm, peak size 171 
nm (Figure 4(A)) and a low polydispersity index of 0.174. The zeta potential was also measured, with 
a value corresponding to −28.2 mV. 
Nanoparticles from the coumarin-containing PLGA derivative, 29, presented a spherical and 
smooth surface, with no aggregation (Figure 3 (C) and (D)) and size range of 174–289 nm. DLS results 
showed an average particle size of 273 nm, peak size 219 nm (Figure 4(B)), a polydispersity value of 
0.146, and a zeta potential of −56.0 mV. This high zeta potential value may be explained by the 
presence of both the triazole ring and amide bonds towards the exterior of the particles, as expected 
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Figure 2. Size profiles of na oparticles from PEG derivatives, measured by DLS. (A) Galactoc njugate
20. (B) Galactoc njugate 24. (C) Mannoc njugate 25.
PLGA glucoc njugate 28 was capable of forming spherical na oparticles, with a smooth surface
and with practically no aggregation as seen i Figure 3A,B. The particles presented a size range of
114–234 nm. DLS gave similar results, with an average particle size of 189 nm, peak size 171 nm
(Figure 4A) and a low polydispersity index of 0.174. The zeta potential was also measured, with a
value corresponding to −28.2 mV.
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Figure 3. SEM micrographs of PLGA derivatives after oil-in-water emulsification method to form
nanoparticles. (A,B) c rrespond to glucoconjugate 28 and (C,D) correspond to cou arin-containing
PLGA derivative 29. Left images have a magnification of 10,000 times, with the bar corresponding to
1 µm. Right images have a magnification of 40,000 times, with the bar corresponding to 100 nm.
Molecules 2020, 25, 1744 10 of 21
Molecules 2020, 25, x FOR PEER REVIEW 10 of 21 
 
 
Figure 3. SEM micrographs of PLGA derivatives after oil-in-water emulsification method to form 
nanoparticles. (A) and (B) correspond to glucoconjugate 28 and (C) and (D) correspond to coumarin-
containing PLGA derivative 29. Left images have a magnification of 10,000 times, with the bar 
corresponding to 1 m. Right images have a magnification of 40,000 times, with the bar corresponding 
to 100 nm. 
   
Figure 4. Size profiles of nanoparticles from PLGA derivatives, measured by DLS. (A) Glucoconjugate 
28. (B) Coumarin-containing derivative 29. 
 
3. Materials and Methods  
All reagents used were purchased from Sigma-Aldrich/Merck, Carbosynth or Fluka. The solvents 




































Figure 4. Size profiles of nanoparticles from PLGA derivatives, measured by DLS. (A) Glucoconjugate
28. (B) Coumarin-containing derivative 29.
Nanoparticles from the coumarin-containing PLGA derivative, 29, presented a spherical and
smooth surface, with no aggregation (Figure 3C,D) and size range of 174–289 nm. DLS results showed
an average particle size of 273 nm, peak size 219 nm (Figure 4B), a polydispersity value of 0.146, and a
zeta potential of −56.0 mV. This high zeta potential value may be explained by the presence of both
the triazole ring and amide bonds towards the exterior of the particles, as expected by the technique
employed for their formation.
3. Materials and Methods
All reagents used were purchased from Sigma-Aldrich/Merck, Carbosynth or Fluka. The solvents
used as reaction media were dried according to the procedures described in the literature [45].
Briefly, DMF was dried with barium oxide, filtered, distilled and stored with 3Å molecular sieves.
Dichloromethane (DCM) was distilled from calcium hydride under an argon atmosphere and used
immediately. Propargyl alcohol was dried overnight with potassium carbonate, distilled and used
immediately. PEG was purchased from Sigma-Aldrich, with an average molecular weight of 1000.
D,L-poly(lactic-glycolic acid) (PLGA) 50:50, with a molecular weight range of 7000–17,000 was
purchased from Sigma-Aldrich. Column chromatography was performed using Carlo Erba’s silica
gel, 40–63 µm mesh. Preparative TLC was performed using silica gel 60GF DGF254 purchased
from Macherey-Nagel.
3.1. Methods for Compounds Characterization
Melting points were measured using an Electrothermal Melting Point Apparatus. Optical rotations
were measured using a Bellingham and Stanley Ltd (Department of Chemistry FCT-NOVA; Portugal).
ADP410 Polarimeter, at sodium D line (Department of Chemistry FCT-NOVA; Portugal). Nuclear
magnetic resonance spectra were obtained using a Bruker ARX 400 MHz (Department of Chemistry
FCT-NOVA; Portugal) for 1H and 101 MHz for 13C. FT-IR spectra were recorded using a Bruker
Tensor 27 (Department of Chemistry FCT-NOVA; Portugal). UV spectra were recorded on a Perkin
Elmer Lambda 35 (Department of Chemistry FCT-NOVA; Portugal, using a quartz cell (Department of
Chemistry FCT-NOVA; Portugal). Emission data were recorded on a Perkin Elmer LS 45 Luminescence
Spectrometer, using a quartz cell (Department of Chemistry FCT-NOVA; Portugal). High resolution
mass spectra were recorded on a Bruker Microtof using electrospray ionization, flow injection analysis
and time-of-flight detector. MALDI spectra were recorded on a Bruker Ultraflex III TOF/TOF using
HCCA as the matrix (Unidade de Espectrometria de Massas e Proteómica; Spain). DLS and zeta
potential measurements were performed using Horiba Scientific Nano Particle Analyzer SZ-100
(Department of Chemistry FCT-NOVA; Portugal) with 1 mg of particles in 1 mL of filtered, ultra-pure
water, at 25 ◦C. SEM micrographs were obtained with a JEOL JSM 7001 scanning electron microscope
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(Electron Microscopy Laboratory of Instituto Superior Técnico; Portugal) with an accelerating voltage of
10 kV, after chromium-coating under argon atmosphere the previously fixed samples onto metallic studs.
3.2. Nanoparticles Preparation
Polymer matrix (50 mg) was dissolved in 5 mL of DCM and poured into 8.0 mL of aqueous PVA
2%. The resulting oil-in-water preparation was sonicated at 60 W for a minute, in periods of 10 s.
The resulting emulsion was magnetically stirred overnight. The resulting suspension was centrifuged,
and the pellet was washed three times with deionized water.
3.3. Synthetic Procedures
3.3.1. Ethyl 3-(7-Hydroxy-4,8-Dimethyl-2-oxo-2H-Chromen-3-yl)propanoate (1)
3-Methylresorcinol (11.020 g, 96.9 mmol) was dissolved in dry ethanol (50 mL) with magnetic
stirring. Diethyl 2-acetylglutarate (21.0 mL, 96.7 mmol) was added and the reaction flask was cooled
to 0 ◦C and dried hydrogen chloride was passed through the flask for 3 h, and the reaction mixture
was maintained at ambient temperature for 16 h. Cool water (500 mL) was added and the resulting
precipitate was collected and dried, affording 1 (16.833 g, 60%) as a beige solid. m.p. = 145–148 ◦C;
FT-IR (NaCl) v̄max: 3263 (br, OH st), 2983 (s, C-H w), 1731–1703 (s, O-C=O st), 1619 (br, C=C m) cm−1;
1H NMR (400 MHz, CDCl3) δ: 7.27 (d, J = 8.7 Hz, 1H, H-5), 6.78 (d, J = 8.7 Hz, 1H, H-6), 4.15 (q,
J = 7.1 Hz, 2H, H-16), 2.98 (t, J = 7.6 Hz, 2H, H-13), 2.63 (t, J = 7.5 Hz, 2H, H-14), 2.40 (s, 3H, H-12), 2.27
(s, 3H, H-11), 1.26 (t, J = 7.2 Hz, 3H, H-17); 13C NMR (101 MHz, CDCl3) δ: 173.6 (C-15), 162.5 (C-2),
156.9 (C-7), 151.7 (C-9), 148.5 (C-4), 122.5 (C-5), 120.2 (C-3), 113.8 (C-10), 111.9 (C-6), 111.5 (C-8), 60.8
(C-16), 32.9 (C-14), 23.2 (C-13), 15.0 (C-12), 14.2 (C-17), 8.0 (C-11).
3.3.2. Ethyl 3-(4,8-Dimethyl-2-oxo-7-(Prop-2-yn-1-yloxy)-2H-Chromen-3-yl)propanoate (2)
Compound 1 (0.992 g, 3.4 mmol) was dissolved in dry acetone (8.3 mL), and anhydrous potassium
carbonate (1.665 g, 12.1 mmol) was added. The reaction mixture was kept under constant stirring for
30 min, and then propargyl bromide (0.5 mL, 4 mmol) was added and the mixture was refluxed for 4 h.
After cooling to room temperature, the solvent was evaporated and the crude product was dissolved
in DCM (10 mL), washed four times with deionized water (4 × 15 mL), dried over anhydrous sodium
sulfate, filtered and evaporated, affording 2 (1.093 g, 98%) as a beige solid m.p. = 151–152 ◦C; 1H NMR
(400 MHz, CDCl3) δ: 7.45 (d, J = 8.9 Hz, 1H, H-5), 6.96 (d, J = 8.9 Hz, 1H, H-6), 4.80 (d, J = 2.4 Hz, 2H,
H-1’), 4.12 (q, J = 7.1 Hz, 2H, H-16), 2.97 (t, J = 7.6 Hz, 2H, H-13), 2.60 (t, J = 7.7 Hz, 2H, H-14), 2.54 (t,
J = 2.5 Hz, 1H, H-3’), 2.43 (s, 3H, H-12), 2.32 (s, 3H, H-11), 1.24 (t, J = 7.1 Hz, 3H, H-17); 13C NMR (101
MHz, CDCl3) δ: 172.9 (C-15), 161.7(C-2), 157.4 (C-7), 151.4 (C-9), 147.4 (C-4), 122.4 (C-5), 121.8 (C-3),
115.0 (C-10), 114.7 (C-8), 108.2 (C-6), 78.2 (C-2’), 76.0 (C-3’), 60.5 (C-16), 56.4 (C-1’), 32.7 (C-13), 23.2
(C-14), 15.0 (C-12), 14.21 (C-17), 8.3 (C-11).
3.3.3. 3-(4,8-Dimethyl-2-oxo-7-(Prop-2-yn-1-yloxy)-2H-Chromen-3-yl)propanoic Acid (3)
Compound 2 (0.822 g, 2.5 mmol) was dissolved in ethanol (20.0 mL), and 0.25 M sodium hydroxide
aqueous solution (12 mL) was added. The reaction was stirred at 80 ◦C for 1 h, cooled down to
room temperature, and deionized water (20 mL) was added. The mixture was acidified with 1 M
hydrochloric acid to pH 1 and the precipitate obtained was filtered and the resulting solid was dried,
affording 3 (0.712 g, 95%) as a white solid. m.p. = 181–183 ◦C; FT-IR (NaCl) v̄max:: 3389 (br, OH st),
3055 (s, C-H w), 2943 (s, C-H w), 2228 (br, C≡C st), 1763-1704 (s, O-C=O st), 1641 (br, C=C m) cm−1; 1H
NMR (400 MHz, DMSO-d6) δ: 7.63 (d, J = 8.9 Hz, 1H, H-5), 7.10 (d, J = 9.0 Hz, 1H, H-6), 4.95 (s, 2H,
H-1’), 3.61 (t, J = 2.7 Hz, 1H, H-3’), 2.77 (t, J = 7.8 Hz, 2H, H-13), 2.40–2.35 (m, 4H, H-12,14), 2.18 (s, 3H,
H-11); 13C NMR (101 MHz, DMSO-d6) δ: 173.8 (C-15), 160.7 (C-2), 157.0 (C-7), 150.5 (C-9), 147.7 (C-4),
123.3 (C-5), 121.2 (C-3), 114.3 (C-10), 112.6 (C-8), 108.8 (C-6), 79.0 (C-2’), 78.7 (C-3’), 56.3 (C-1’), 32.6
(C-14), 23.0 (C-13), 14.7 (C-12), 8.0 (C-11).
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3.3.4. 7-(Prop-2-yn-1-yloxy)-2H-Chromen-2-One (4)
Potassium iodide (2.454 g, 14.7 mmol) and potassium carbonate (2.045 g, 14.7 mmol) were added
to a solution of umbelliferone (2.011 g, 12.4 mmol) in DMF (30 mL) under magnetic stirring and argon
atmosphere. Then, propargyl bromide 80% in toluene (1.7 mL, 14.8 mmol) was added drop-wise and
the reaction was heated at 80 ◦C. After the completion of the reaction (2 h 30 min), dichloromethane
was added (40 mL) and the mixture was transferred to a separating funnel and washed three times
with water (3 × 20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and
concentrated to afford 7-(prop-2-yn-1-yloxy)-2H-chromen-2-one, 4, as a light brown solid (2.382 g, 96%
without purification) and was used, as such, for further reactions. m.p. = 114–115 ◦C; UV (DCM) λmax
= 319 nm; Em (DCM) λmax = 386 (λexc = 320 nm); FT-IR (NaCl) v̄max: 3266 (C-H st), 3084 (ar C-H st),
2119 (C=C st), 1701 (C=O st), 1614 (C=C st) cm−1; 1H NMR (400 MHz, CDCl3) δ: 7.65 (d, J=9.5 Hz, 1H,
H-4), 7.41 (d, J=8.5 Hz, 1H, H-5), 7.02–6.81 (m, 2H, H-6 and H-8), 6.28 (d, J = 9.5 Hz, 1H, H-3), 4.77 (d,
J = 2.3 Hz, 2H, H-9), 2.58 (t, J = 2.2 Hz, 1H, H-11); 13C NMR (101 MHz, CDCl3) δ: 161.0 (C-2), 160.6
(C-7), 155.7 (C-8a), 143.3 (C-4), 128.8 (C-5), 113.7 (C-3), 113.2 (C-4a), 113.1 (C-6), 102.2 (C-8), 77.4 (C-10),
76.6 (C-11), 56.2 (C-9).
3.3.5. Prop-2-yn-1-yl 2-oxo-2H-Chromene-3-Carboxylate (5)
DCC (2.600, 12.6 mmol) and DMAP (0.129 g, 1.1 mmol) were added to a solution of coumarin-3-
carboxylic acid (2.000 g, 10.5 mmol) in DCM (30 mL). The reaction mixture was stirred magnetically
under an argon atmosphere and propargyl alcohol (1.2 mL, 21.0 mmol) was added drop-wise. After
stirring overnight the mixture was filtered, transferred to a separating funnel and washed three times
with acetic acid (5%, 3 × 15 mL) and then with water (20 mL). The organic phase was dried over
anhydrous sodium sulfate, filtered and the solvent evaporated under vacuum. The residue was washed
with petroleum ether to afford the desired product as a white solid (2.399 g quantitative yield without
purification) and used for further reactions. m.p. = 125-127 ◦C; UV (DCM) λmax = 294 nm; Em (DCM)
λmax = 418 (λexc = 320 nm); FT-IR (NaCl) v̄max:: 3315, 3228 (C≡C-H st), 3058 (ar C-H st), 2936, 2852, 2117
(C≡C st), 1717 (C=O), 1612 (C=C st) cm−1; 1H NMR (400 MHz, CDCl3) δ: 8.61 (s, 1H, H-4), 7.87–7.45
(m, 2H, H-5 and H-7), 7.36 (m, 2H, H-6 and H-8), 4.95 (d, J = 2.1 Hz, 2H, H-9), 2.56 (t, J = 2.0 Hz, 1H,
H-11); 13C NMR (101 MHz, CDCl3) δ: 162.1 (C-9), 156.4 (C-2), 155.3 (C-8a), 149.6 (C-7), 134.8 (C-5),
129.7 (C-4), 125.0 (C-6), 117.7 (C-4a), 117.2 (C-8), 116.9 (C-3), 75.7 (C-12), 53.2 (C-10). C-11 is probably
obscured by the CDCl3 signal.
3.3.6. 4-Methyl-7-(Prop-2-yn-1-yloxy)-2H-Chromen-2-One (6)
7-Hydroxy-4-methyl coumarin (3.532 g, 20.1 mmol) was dissolved in dry acetone (30 mL) and
anhydrous potassium carbonate (3.209 g, 20.2 mmol) was added. The reaction was magnetically stirred
for 30 min, and propargyl bromide (2.7 mL, 24.1 mmol) was added. The reaction flask was heated at
50 ◦C and reacted for 18 h. The solvent was evaporated, and the residue was dissolved in DCM (20 mL)
and washed four times with water (20 mL). The organic phase was dried over anhydrous sodium
sulfate, filtered and evaporated, to afford product 6 (3.786 g, 88%) as a beige solid. m.p. = 132–134 ◦C;
FT-IR (NaCl) v̄max: 3304 (s, ≡C-H, st), 3069 (s, C-H m), 2924 (s, C-H m), 1764–1721 (s, O-C=O st), 1619
(br, C=C m), 1262 (s, CO-O m) cm−1; 1H NMR (400 MHz, CDCl3) δ: 7.52 (d, J = 9.5 Hz, 1H, H-5),
7.00–6.80 (m, 2H, H-6,8), 6.15 (s, 1H, H-3), 4.76 (d, J = 2.5 Hz, 2H, H-1’), 2.59 (t, J = 2.5 Hz, 1H, H3’),
2.40 (s, 3H, H-11); 13C NMR (101 MHz, CDCl3) δ: 161.1 (C-2), 160.4 (C-7), 155.0 (C-4), 152.5 (C-9), 125.7
(C-5), 114.3 (C-10), 112.7 (C-6), 112.4 (C-3), 102.2 (C-8), 77.5 (C-2’), 76.5 (C-3’), 56.2 (C-1’), 18.7 (C-11).
3.3.7. 2-Azidoethanamine (7)
2-Bromoethylamine hydrobromide (6.162 g, 30.1 mmol) was added to an aqueous sodium azide
solution (3.5 M, 26 mL). The reaction was kept at 85 ◦C for 21 h, and then cooled to 0 ◦C. Potassium
hydroxide (7.985 g, 142.3 mmol) was then added in three portions and the pH reached 10. The compound
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was extracted with diethyl ether (4 × 25 mL) and the organic phase was dried over anhydrous sodium
sulfate, filtered and the solvent evaporated at 28 ◦C to a green mixture of 2.688 g containing 2.105 g
(24.4 mmol, 81%) of the desired compound in ether. The yield of this reaction was determined by NMR.
The solvent was never fully evaporated due to the sensitive and explosive nature of 7. FT-IR (NaCl)
v̄max: 3447 (br, N-H st), 2939 (s, C-H w), 2093 (s, N3 st) cm−1; 1H NMR (400 MHz, CDCl3) δ: 3.36 (t,
J = 5.7 Hz, 2H, H-2), 2.87 (t, J = 5.7 Hz, 2H, H-1), 1.71 (s, 2H, NH2); 13C NMR (101 MHz, CDCl3) δ: 54.7
(C-2), 41.4 (C-1).
3.3.8. 7-((1-(2-Aminoethyl)-1H-1,2,3-Triazol-4-yl)methoxy)-4-Methyl-2H-Chromen-2-One (8)
Compound 7 (0.534 g, 6.2 mmol) was dissolved in freshly distilled THF (6.0 mL). DIPEA
(0.2 mL), copper iodide (0.044 g, cat.) and 6 (2.657 g; 12.4 mmol) were added. The mixture was kept
under magnetic stirring for 1.5 h. The mixture was purified by silica gel chromatography using
chloroform/methanol (8: 2) as eluent, affording 8 as a yellow solid (1.396 g, 75%). m.p. = 114–116 ◦C;
1H NMR (400 MHz, DMSO-d6) δ: 8.26 (s, 1H, H-5), 7.69 (d, J = 8.8 Hz, 1H, H-5’), 7.15 (d, J = 2.5 Hz,
1H, H-3’), 7.04 (dd, J = 8.8, 2.4 Hz, 1H, H-6’), 6.22 (t, J = 1.3 Hz, 1H, H-8’), 5.26 (s, 2H, H-6), 4.34 (t,
J = 6.2 Hz, 2H, H-2), 2.97 (t, J = 6.2 Hz, 2H, H-1), 2.40 (d, J = 1.3 Hz, 3H, H-11’), 1.90 (s, 2H, NH2); 13C
NMR (101 MHz, DMSO-d6) δ: 161.1 (C-2’), 160.1 (C-7’), 154.7 (C-4’), 153.4 (C-9’), 141.7 (C-4), 126.5
(C-5’), 125.1 (C-5), 113.4 (C-14’), 112.6 (C-6’), 111.3 (C-8’), 101.6 (C-3’), 61.7 (C-6), 54.9 (C-2), 52.5 (C-1),
18.1 (C-11’); MS (ESI+) m/z: calc: for C15H17N4O3 (M + H+) 301.1295, found 301.1299.
3.3.9. 1-O-Propargyl-D-Glucopyranoside (9)
D-glucose (4.149 g, 23.0 mmol) was dissolved in propargyl alcohol (7.8 mL, 132.0 mmol), and
sulfuric acid immobilized in silica gel (150.4 mg) was added. The reaction mixture was heated at
65 ◦C overnight. After cool down to room temperature, the mixture was purified by silica column
chromatography using an ethyl acetate/acetone/water (10:10:1) mixture, affording 9 as a mixture
of α and β anomers, 2:1 ratio. Sulfuric acid supported on silica was prepared accordingly with
the procedure described by Roy and Mukhopadhyay [36]. For detailed characterization, the α, β
mixture 9 was per-O-acetylated using acetic anhydride to give the α, β-propargylated per-acetylated
glucopyranose 12.
3.3.10. 1-O-Propargyl-D-Galactopyranoside (10)
D-galactose (2.000 g, 11.1 mmol), propargyl alcohol (3.2 mL, 55.6 mmol) and sulfuric acid supported
on silica (72.5 mg) were mixed together under magnetic stirring and an argon atmosphere. The reaction
flask was heated at 65 ◦C overnight, and after cooling the mixture was chromatographed [ethyl acetate
(AcOEt), then 10:10:1 AcOEt/acetone/water] affording 45% of propargylated galactopyranose 10 as
a yellowish oil (1.099 g, 0.5 mmol, 2:1 α/β ratio). Sulfuric acid supported on silica was prepared
accordingly with the procedure described by Roy and Mukhopadhyay [36]. [α]16D = +110.0
◦ (C=1.4,
MeOH); FT-IR (NaCl), v̄max: 3382 (br, O-H st), 2925 (w, C-H st) cm−1; 1H NMR (400 MHz, D2O) δ: 5.04
(s, 2H, H-1α), 4.50 (d, J = 7.9 Hz, 1H, H-1β), 4.43–4.39 (m, 1H), 4.26 (dd, J = 5.8, 2.2 Hz, 4H), 3.92 (s, 2H),
3.91–3.83 (m, 3H), 3.81–3.74 (m, 5H), 3.72–3.63 (m, 7H), 3.59 (dd, J = 9.9, 3.3 Hz, 1H), 3.50–3.41 (m, 1H),
2.86–2.80 (m, 1H); 13C NMR (101 MHz, D2O) δ: 101.1, 97.3, 79.0, 78.9, 76.2, 75.9, 75.3, 72.7, 71.2, 70.5,
69.4, 69.1, 68.6, 67.9, 60.9, 60.9, 56.5, 54.8.
3.3.11. 1-O-Propargyl-D-Mannopyranoside (11)
D-mannose (2.000 g, 11.1 mmol), propargyl alcohol (3.2 mL, 55.6 mmol) and sulfuric acid supported
on sílica (58 mg) were mixed together under magnetic stirring and argon atmosphere. The reaction flask
was heated at 65 ◦C overnight, and after cooling the mixture was purified by column chromatography
(AcOEt, then 10:10:1 AcOEt/acetone/water) affording propargylated mannopyranose 11 as a yellowish
oil (0.928 g, 38%, 2:1 α/β ratio). Sulfuric acid supported on silica was prepared accordingly to the
procedure described by Roy and Mukhopadhyay [36]. FT-IR (NaCl), v̄max: 3289 (br), 2930 (w) cm−1;
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1H NMR (400 MHz, D2O) δ: 5.00 (s, 1H, H-1α), 4.40–4.20 (m, 2H, H-1’), 3.92 (s, 1H), 3.89–3.81 (m, 1H),
3.81–3.69 (m, 2H), 3.69–3.57 (m, 2H), 2.89 (s, 1H, C-3’); 13C NMR (101 MHz, D2O) δ: 98.7 (C-1α), 79.0,
76.3, 73.1, 70.5, 69.9, 66.6, 60.8, 54.6 (C-1’).
3.3.12. 1-O-Propargyl-2,3,4,6-Tetra-O-Acetyl-D-Glucopyranoside (12)
Glucopyranoside 9 (3.418 g, 15.7 mmol) reacted with acetic anhydride (16.2 mL, 171.6 mmol) in
dry pyridine (30.0 mL) for 4 h under an argon atmosphere. The solvent was then evaporated and the
remaining solid was dissolved in dichloromethane and purified by silica column chromatography
using hexane/ethyl acetate (1:1) affording 12 as a colorless oil (4.998 g, 82%). FT-IR (NaCl) v̄max: 3278 (s,
≡C-H w), 2961 (s, C-H w), 1749 (s, O-C=O st) cm−1; 1H NMR (400 MHz, CDCl3) δ: 5.49 (t, J = 9.8 Hz,
1.17H, H-3), 5.30–5.27 (m, 1H, H-1α), 5.15–4.97 (m, 2H), 4.92 (dd, J = 10.3, 3.8 Hz, 1H), 4.78 (d, J = 8.0 Hz,
0.42H H-1β), 4.38 (d, J = 2.3 Hz, 1H), 4.28 (d, J = 2.4 Hz, 2H, H-1’), 4.26 (d, J = 4.1 Hz, 1H), 4.18–4.03 (m,
3H), 3.78–3.70 (m, 0.42H, H-5β), 2.48 (t, J = 2.3 Hz, 0.41H, H-3’β), 2.46 (t, J = 2.3 Hz, 1H, H-3’α), 2.06 (s,
19H, CH3).
3.3.13. 1-[1’-Ethylamine-Triazolyl-4]-1-Methyl-2,3,4,6-Tetra-O-Acetyl-D-Glucopyranoside (13)
Compound 7 (0.037 g, 0.4 mmol) was dissolved in 4,0 mL of freshly distilled THF, and
DIPEA (0.1 mL, 0.6 mmol), copper iodide (0.027 g, cat.) and 12 (0.237 g, 0.6 mmol) were added.
After 2.5 h the solvent was evaporated and the mixture was purified by column chromatography using
chloroform/methanol (9:1), affording 13 (0.138, 73%) as a yellow solid. m.p. = 60–65 ◦C (degradation);
FT-IR (NaCl) v̄max: 3421 (br, NH st), 1745 (s, O-C=O st) cm−1; 1H NMR (400 MHz, CDCl3) δ: 7.68 (s,
1H, Hα-5’), 7.64 (s, 0.48H, Hβ-5’), 5.49 (t, J = 9.8 Hz, 1H, H-3), 5.22 (d, J = 4.1 Hz, 1H, H-1α), 5.09 (s,
1H, H-2), 4.91–4.83 (m, 3H,), 4.70 (d, J = 12.5 Hz, 2H, H-1β,6), 4.44 (t, J = 5.9 Hz, 3H, H-7’), 4.31–4.22
(m, 2H), 4.11 (dd, J = 10.1, 3.1 Hz, 2.38H), 3.75 (d, J = 7.8 Hz, 0.8H, H-5), 3.26 (s, 3H, H-8’), 2.13–1.98
(m, 20H, CH3); 13C NMR (101 MHz, CDCl3) δ: 170.7–169.5 (C-Ac), 144.1 (C-4’β), 143.5 (C-4’α), 123.7
(C-5’β), 123.6 (C-5’α), 99.9 (C-1α), 95.0 (C-1β), 72.8–72.0 (C-5), 71.9–71.3 (C-2), 70.7–70.6 (C-3), 68.5–68.3
(C-6), 67.5 (C-4), 63.0 (C-6’), 61.8 (C-6β), 61.3 (C-6α), 60.8 (C-7’), 41.7 (C-8’), 20.8–20.6 (CH3).
3.3.14. 1-[1’-Ethylamine-Triazolyl-4]-1-O-Methyl-D-Glucopyranoside (14)
Compound 13 (0.110 g, 0.2 mmol) was dissolved in dry methanol at ice-bath temperature, and
sodium methoxide was added (0.012 g, 0.2 mmol). The reaction was allowed to warm to room
temperature and stirred for a further 3 h. Pre-activated and thoroughly washed acidic Dowex was
added until the pH changed from basic to acidic. The solution was filtered and the solvent evaporated
to give compound 14 (0.071 g, 0.2 mmol, 100%) as a white foam. Due to the complex anomeric mixture
this compound’s characterization was based on the spectra of per-O-acetyl compound 13.
3.3.15. 5’-O-[(4-Methylphenyl)sulfonyl] Thymidine (15)
In a round bottom flask 2’-deoxythymidine (1.569 g, 6.5 mmol) was dissolved in dry pyridine
(7.5 mL) and the flask cooled in an ice bath for 1 h. Tosyl chloride (1.236 g, 6.5 mmol) dissolved in dry
pyridine (2.5 mL) was added dropwise and the reaction allowed to attain room temperature during 17
h. The solvent was then evaporated, and the resulting crude product was dissolved in ethanol at 75 ◦C
and then cooled down to −10 ◦C for 12 h. The resulting crystals of 15 were filtered and washed with
cold ethanol (3 × 1.0 mL, 1.889 g, 54%). m.p. = 189–191 ◦C; FT-IR (NaCl) v̄max: 3374 (br, OH st), 3067 (s,
C-H w), 2924 (s, C-H w), 1724–1694 (s, N-C=O st) cm−1; 1H NMR (400 MHz, DMSO-d6) δ: 11.31 (s, 1H,
NH), 7.79 (d, J = 8.2 Hz, 2H, H-12), 7.47 (d, J = 8.1 Hz, 2H, H-13), 7.38 (s, 1H, H-6), 6.15 (t, J = 6.9 Hz,
1H, H-1), 5.43 (d, J = 4.2 Hz, 1H, OH), 4.26 (dd, J = 10.9, 3.2 Hz, 1H, H-3), 4.19–4.15 (m, 2H, H-5), 3.86
(dt, J = 6.8, 3.5 Hz, 1H, H-4), 2.41 (s, 3H, H-15), 2.19–2.04 (M, 2H, H-2), 1.77 (s, 3H, H-8); 13C NMR
(101 MHz, DMSO-d6) δ: 163.6 (C-9), 150.4 (C-10), 145.1 (C-11), 135.9 (C-14), 132.1 (C-6), 130.2 (C-13),
127.6 (C-12), 109.8 (C-7), 84.0 (C-1), 83.2 (C-4), 70.1 (C-3), 69.9 (C-5), 38.3 (C-2), 21.1 (C-15), 12.1 (C-8).
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3.3.16. 5’-Azide-5’-Deoxythymidine (16)
Method I—conventional heating: compound 15 (0.562 g, 1.4 mmol) was dissolved in DMF (5.0 mL),
and sodium azide was added (0.407 g, 6.4 mmol). The reaction mixture was heated to 85 ◦C on an oil
bath for 15 h. The solvent was then evaporated under reduced pressure and the mixture was purified
by silica gel column chromatography using chloroform/methanol (9:1) as eluent, affording 16 (0.325 g,
87%) as a beige solid.
Method II—microwave irradiation: compound 15 (0.817 g, 2.1 mmol) was dissolved in DMF
(5.0 mL), and sodium azide (0.620 g, 10.3 mmol) was added. The mixture was irradiated with
microwaves with a power of 250 W at a temperature of 100 ◦C, for two 1 min cycles. The solvent
was evaporated under reduced pressure and the mixture was purified by column chromatography
(chloroform/methanol, 9:1) to afford 16 (0.505 g, 90%) as a beige solid. m.p. = 156–158 ◦C; FT-IR
(NaCl) v̄max: 3422 (br,OH st), 2926 (s, C-H w), 2103 (s, N3 st), 1701–1685 (s, N-C=O st) cm−1; 1H NMR
(400 MHz, CD3OD) δ: 7.56 (s, 1H, H-6), 6.29 (t, J = 6.8 Hz, 1H, H-1), 4.38 (dt, J = 6.5, 4.1 Hz, 1H, H-3),
3.99 (q, J = 4.0 Hz, 1H, H-4), 3.63 (qd, J = 13.2, 4.4 Hz, 2H, H-5), 2.37–2.25 (m, J = 6.9 Hz, 2H, H-2), 1.92
(s, 3H, H-8); 13C NMR (101 MHz, CD3OD) δ: 166.3 (C-9), 152.3 (C-10), 137.8 (C-6), 111.9 (C-7), 86.4
(C-4), 86.3 (C-1), 72.5 (C-3), 53.4 (C-5), 40.2 (C-2), 12.5 (C-8).
3.3.17. α-Coumarin 3-Carboxylate-ω-Hydroxyl PEG1000 (17)
Coumarin 3-carboxylic acid (0.456 g, 2.4 mmol) was dissolved in DCM (15 mL) with magnetic
stirring and under an argon atmosphere. DCC (0.990 g, 4.8 mmol) and DMAP (0.293 g, 2.4 mmol)
were added. After 45 min, a white precipitate was observed and PEG1000 (2.000, 2.0 mmol) was added.
The reaction flask was heated at 40 ◦C for 18 h. Then, the mixture was filtrated and washed two times
with aqueous acetic acid 5% (2 × 20 mL) and once with water (20 mL). The organic phase was dried
over sodium sulfate, filtered, concentrated and purified by column chromatography (chloroform to 9:1
chloroform/methanol gradient), affording the required product in 98% yield (2.307 g, 1.97 mmol) as
a yellowish wax. FT-IR (NaCl), v̄max: 3512 (br, O-H st), 2870 (s, C-H st), 1766 (s, C=O st) cm−1; UV
(DCM) λmax = 292 nm; Em (DCM) λmax = 386 nm (λexc = 320 nm); 1H NMR (400 MHz, CDCl3) δ: 8.57
(s, 1H, H-4), 7.65 (m, 2H, H-Ar), 7.36 (m, 2H, H-Ar), 4.50 (t, J = 4.6 Hz, 2H, O-CH2-PEG), 3.85 (t, 2H,
O-CH2CH2-PEG), 3.79–3.56 (m, 84H, PEG); 13C NMR (101 MHz, CDCl3) δ: 162.8 (C-9), 156.6 (C-2),
155.2 (C-8ª), 148.8, 134.4 (C-Ar), 129.6 (C-Ar), 124.9 (C-Ar), 119.9, 119.8 (C-3 and C-4a), 116.8 (C-Ar),
72.5 (PEG), 70.5 (PEG), 70.2 (PEG), 68.9 (O-CH2-CH2-PEG), 64.8 (O-CH2-CH2-PEG), 61.6 (PEG).
3.3.18. α-Coumarin 3-Carboxylate-ω-Tosyl PEG1000 (18)
Polymer 17 (3.968 g, 3.4 mmol) was dissolved in DCM (25 mL) and triethylamine (0.7 mL, 5.1 mmol)
with magnetic stirring and argon atmosphere. Tosyl chloride (0.965 g, 5.1 mmol) was then added slowly
in portions. After 18 h, the reaction mixture was evaporated and purified by column chromatography
(chloroform to 9:1 CHCl3/methanol, gradient), to afford 18 as a yellowish wax in 92% yield (4.001 g, 3.0
mmol). FT-IR (NaCl), v̄max: 2872 (s, C-H st), 1761 (s, C=O st), 1108 (s, O=S=O sym st) cm−1; UV (DCM)
λmax = 285 nm; Em (DCM) λmax = 412.5 nm (λexc = 320 nm); 1H NMR (400 MHz, CDCl3) δ: 8.57 (s, 1H,
H-4), 7.80 (d, J = 8.2 Hz, 2H, H-Ar), 7.73–7.57 (m, 2H, H-Ar), 7.35 (m, 4H, H-Ar), 4.50 (t, J = 4.8 Hz, 4H,
PEG), 4.16 (t, J = 4.8 Hz, 2H, PEG), 3.89–3.81 (t, J = 4.8 Hz, 4H, PEG), 3.76–3.49 (m, 120H, PEG), 2.45 (s,
3H, CH3); 13C NMR (101 MHz, CDCl3) δ: 162.8 (C-9), 156.6, 155.2, 148.9 (C-4), 144.8, 134.5, 133.0, 129.8,
129.6, 128.0, 124.9, 117.9, 117.8, 116.8, 70.7, 70.6, 70.6, 70.5 (PEG), 69.3 (PEG), 68.9 (PEG), 68.6 (PEG),
64.9 (PEG), 21.6 (C-14).
3.3.19. α-Coumarin 3-Carboxylate-ω-Azide PEG1000 (19)
Polymer 18 (4.008 g, 3.0 mmol) was dissolved in DMF (32 mL) and sodium azide (0.393 g, 6.0 mmol)
was added in portions with stirring under an argon atmosphere. After 18 h, the DMF was evaporated
under reduced pressure and water was added to the resulting residue. The mixture was extracted
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with DCM, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column
chromatography (chloroform to 9:1 chloroform/methanol, gradient), to afford the product as an orange
wax (3.291 g, 91%), and used for further reactions. FT-IR (NaCl), v̄max: 2871 (s, C-H st), 2104 (w, N3 st)
1761 (s, C=O st) cm−1; UV (DCM) λmax = 284 nm; Em (DCM) λmax = 412.5 nm (λexc = 320 nm); 1H
NMR (400 MHz, CDCl3) δ: 8.57 (s, 1H, H-4), 7.79–7.56 (m, 2H, H-5 and H-7), 7.46–7.31 (m, 2H, H-6
and H-8), 4.58–4.41 (m, 2H, O-CH2-CH2-PEG), 4.02–3.33 (m, 90H, PEG); 13C NMR (101 MHz, CDCl3)
δ: 162.8 (C-9), 156.6 (C-2), 155.2 (C-8a), 148.9, 134.5, 129.6, 124.9, 117.9, 117.9, 116.8, 70.6 (PEG), 50.7
(CH2N3).
3.3.20. α-Coumarin 3-Carboxylate-ω-[(1H-1,2,3-triazol-4-yl)methoxygalactopyranosyl] PEG1000 (20)
Azide polymer 19 (0.500 g, 0.4 mmol) was dissolved in THF (4.2 mL) then copper iodide
(0.039 g, 0.2 mmol), DIPEA (0.14 mL, 0.8 mmol) and compound 10 (0.086 g, 0.4 mmol) were added.
The mixture was magnetically stirred under an argon atmosphere for 34 h. After removal of the
solvent under reduced pressure, the residue was suspended in DCM and washed twice with water,
once with brine, dried over anhydrous sodium sulfate, filtered and concentrated. Purification by
preparative chromatography (95:5 chloroform/methanol) afforded 20 as a yellow wax in 18% yield
(0.105 g, 0.1 mmol). FT-IR (NaCl), v̄max: 3458 (O-H st), 2876 (C-H st), 1759 (C=O st) cm−1. UV (DCM)
λmax = 293 nm; Em (DCM) λmax = 413 nm (λexc = 320 nm); 1H NMR (400 MHz, CDCl3) δ: 8.57 (s, 1H,
H-4), 8.23–7.99 (m, 1H, H-9’), 7.72–7.61 (m, 2H, H-5 and H-7), 7.40–7.32 (m, 2H, H-6 and H-8), 5.05
(s, 1H, H-1’), 4.87 (s, 1H, H-6a’), 4.74 (s, 1H (H-6b’), 4.62 (s, 2H, H-3’), 4.50 (s, 2H, H-7’), 4.30–3.34 (m,
100H, PEG); 13C NMR (101 MHz, CDCl3) δ: 162.8, 156.6, 155.2, 149.2 (C-4), 148.9, 134.5 (C-7), 129.6
(C-5), 124.9 (C-9’ and C-6), 117.9, 117.9, 116.8 (C-8), 98.8 (C-1’), 70.5 (PEG), 69.9 (C-2’), 69.0 (C-4’), 68.9
(PEG), 64.9 (C-7’), 62.1, 60.3 (C-6’), 52.9, 51.1 (C-3’).
3.3.21. α-Tosyl-ω-Tosyl PEG1000 (21)
PEG (5.000 g, 5 mmol) was dissolved in DCM (50 mL) with magnetic stirring and an argon
atmosphere. Triethylamine (1.6 mL, 11.0 mmol) and tosyl chloride (2.383, 12.5 mmol) were added
and the reaction mixture was heated at 50 ◦C for 15 h. The mixture was concentrated under vacuum
and purified by column chromatography (chloroform to 9:1 chloroform/methanol gradient) affording
quantitatively the product 21 (6.542 g, 100%) as a yellowish wax. FT-IR (NaCl), v̄max: 3511 (br, O-H st),
2873 (s, C-H st) cm−1; 1H NMR (400 MHz, CDCl3) δ: 7.80 (d, J = 6.7 Hz, 4H, H-Ar), 7.35 (d, J = 6.4 Hz,
4H, H-Ar), 4.16 (s, 4H, 2x CH2-OTs), 3.75–3.49 (m, 89H, PEG), 3.38 (s, 2H, PEG), 2.45 (s, 6H, 2x CH3);
13C NMR (101 MHz, CDCl3) δ: 144.8 (C-Ar), 133.1 (C-Ar), 129.8 (C-Ar), 128.0 (C-Ar), 70.8 (PEG), 70.6
(PEG), 70.6 (PEG), 69.3 (PEG), 68.7 (PEG), 21.6 (CH3).
3.3.22. α-Azide-ω-Azide PEG1000 (22)
To a solution of compound 21 (1.488 g, 1.1 mmol) in DMF (18 mL) under magnetic stirring
and argon atmosphere was added sodium azide (0.222 g, 3.4 mmol) and the reaction was heated
at 50 ◦C for 16 h. The solvent was evaporated under reduced pressure and then dichloromethane
(35 mL) was added and the organic phase was washed twice with brine (2 × 20 mL) and once with
water (20 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column
chromatography (chloroform to 9:1 chloroform/methanol stepwise) affording product 22 (0.966 g,
0.9 mmol) as a yellowish wax; 1H NMR (400 MHz, CDCl3) δ: 3.65 (s, 90H, PEG), 3.39 (t, J = 4.5 Hz, 4H,
2× CH2-N3); 13C NMR (101 MHz, CDCl3) δ: 70.7 (PEG), 70.7 (PEG), 70.6 (PEG), 70.6 (PEG), 70.0 (PEG),
50.7 (2× CH2N3).
3.3.23. α-Azide-ω-[7-((1H-1,2,3-Triazol-4-yl)methoxy)-2H-Chromen-2-One)] PEG1000 (23)
Compounds 22 (0.966 g, 0.9 mmol) and 4 (0.184 g, 0.9 mmol), copper iodide (0.101 g, 0.5 mmol),
and DIPEA (0.32 mL, 1.8 mmol) were mixed in THF (8 mL) under magnetic stirring and an argon
atmosphere for 18 h. The solvent was evaporated under reduced pressure and then dichloromethane
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(35 mL) was added. The resulting organic phase was washed three times with water (3 × 20 mL),
dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography
(chloroform to 9:1 chloroform/methanol, gradient) affording product 23 (0.947 g, 82%) as an orange
wax. FT-IR (NaCl) v̄max: 3553 (w, O-H st) 2872 (s, C-H st), 2106 (w, N3 st), 1732 (s, C=O), 1614 (s, C=C
bend) cm−1; UV (DCM) λmax = 322 nm; Em (DCM) λmax = 386 nm (λexc = 320 nm); 1H NMR (400 MHz,
CDCl3) δ: 8.00 (s, 1H, H-8’), 7.66 (d, J = 9.5 Hz, 1H, H-6’), 7.41 (d, J = 8.4 Hz, 1H, H-4’), 7.03–6.88 (m,
2H, H-3’ and H-5), 6.26 (d, J = 9.5 Hz, 1H, H-5’), 5.29 (s, 2H, H-6), 4.60 (t, J = 4.2 Hz, 2H, PEG), 3.90 (t,
J = 4.6 Hz, 4H, PEG), 3.82–3.54 (m, 82H, PEG), 3.39 (t, J = 4.8 Hz, 2H, N3-CH2); 13C NMR (101 MHz,
CDCl3) δ: 161.4 (C-2’), 161.0 (C-7’), 155.7 (C-8a’), 143.4 (C-4), 142.4 (C-6’), 129.0 (C-4’), 124.8 (C-8’), 113.4
(C-5’), 113.0 (C-4a’), 112.8 (C-5), 102.1 (C-3’), 70.7 (PEG), 70.6 (PEG), 70.5 (PEG), 70.4 (PEG), 70.3 (PEG),
70.0 (PEG), 69.3 (PEG), 62.1 (C-6), 50.7 (2× CH2-N3).
3.3.24. α–[7-((1H-1,2,3-triazol-4-yl)methoxy)-2H-Chromen-2-One)]–ω–[(1H-1,2,3-triazol-4-yl)
methoxygalactopyranosyl] PEG1000 (24)
Azide 4 (0.150 g, 0.1 mol), propargylated galactopyranosyl 10 (0.039 g, 0.2 mmol), copper iodide
(0.011 g, 0.06 mmol), DIPEA (0.04 mL, 0.2 mmol), and 2,2’-bipyridine (0.009 g, 0.06 mmol) were
dissolved in THF (1 mL), and mixed together under magnetic stirring and argon atmosphere for 22 h.
The mixture was evaporated under reduced pressure, and the residue was dissolved in chloroform
(10 mL), washed two times with deionized water (10 mL), once with brine (10 mL), dried over
anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (chloroform
to 9:1 chloroform/methanol, stepwise) to afford 24 (0.019 g, 11%) as an orange wax. λ Absmax = 321 nm;
λ Emmax = 383.5 nm (λexc = 320 nm); 1H NMR (400 MHz, CDCl3) δ: 7.93 (s, 2H, H-11 and H-12), 7.66
(d, J = 9.4 Hz, 1H, H-4), 7.40 (d, J = 9.3 Hz, 1H, H-5), 7.02–6.91 (m, 2H, H-6 and H-8), 6.27 (d, J = 9.4 Hz,
1H, H-3), 5.32–5.24 (m, 2H, H-9), 5.10–5.00 (m, 2H, H-1’), 4.93–4.66 (m, 3H), 4.65–4.47 (m, 4H, H-14),
4.47–4.20 (m, 2H), 4.19–3.99 (m, 3H), 3.95–3.78 (m, 10H, PEG), 3.78–3.39 (m, 120H, PEG), 3.24–3.05 (m,
6H, PEG); 13C NMR (101 MHz, CDCl3) δ: 161.4 (C-2), 161.1 (C-7), 155.7 (C-8a), 143.4 (C-4), 142.6 (C-10
and C-13), 128.9 (C-5), 124.6 (C-11 and C-12), 113.3 (C-13), 112.9 (C-4a), 112.8 (C-6), 102.1 (C-8), 72.7
(PEG), 70.5 (PEG), 69.3 (PEG), 62.3 (C-9), 61.6 (PEG), 50.4 (C-14).
3.3.25. α–[7-((1H-1,2,3-Triazol-4-yl)methoxy)-2H-Chromen-2-One)]–ω–[(1H-1,2,3-triazol-4-yl)
methoxymannopyranosyl] PEG1000 (25)
Azide 4 (0.153 g, 0.1 mol), propargylated mannopyranosyl 11 (0.055 g, 0.3 mmol), copper iodide
(0.033 g, 0.18 mmol), DIPEA (0.04 mL, 0.2 mmol) and 2,2’-bipyridine (0.013 g, 0.08 mmol) were
dissolved in THF (1 mL), and mixed together under magnetic stirring and argon atmosphere for 22 h.
The mixture was evaporated under reduced pressure, and the residue was dissolved in chloroform
(10 mL), washed two times with deionized water (10 mL), once with brine (10 mL), dried over
anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (chloroform
to 9:1 chloroform/methanol, stepwise) to afford 25 (0.030 g, 17%) as an orange wax. λ Absmax = 321
nm; λ Emmax = 386.5 nm (λexc = 320 nm); 1H NMR (400 MHz, CDCl3) δ: 8.01–7.81 (m, 2H, H-11 and
H-12), 7.66 (d, J = 9.5 Hz, 1H, H-4), 7.41 (d, J = 8.8 Hz, 1H, H-5), 7.05–6.88 (m, 2H, H-6 and H-8), 6.27
(d, J = 9.4 Hz, 1H, H-3), 5.35–5.22 (m, 2H, H-9), 5.11–4.90 (m, 2H, H-1’), 4.85–4.64 (m, 3H), 4.63–4.48
(m, 5H, H-14), 4.31–2.97 (m, 140H, PEG); 13C NMR (101 MHz, CDCl3) δ: 161.4 (C-2), 161.1 (C-7), 155.7
(C-8a), 143.4 (C-4), 142.7 (C-10 and C-13), 129.0 (C-5), 124.6 (C-11 and C-12), 113.4 (C-3), 112.9 (C-4a),
112.9 (C-6), 102.1 (C-8), 72.7 (PEG), 70.5 (PEG), 69.4 (PEG), 69.0 (PEG), 62.3 (C-9), 50.4 (C-14).
3.3.26. α-3-[3-(4,8-Dimethyl]-7-(2-Propynyloxy)]-Coumarinyl Propanoate-ω-3-[3-(4,8-dimethyl]-7-
(2-propynyloxy)]-coumarinyl propanoate PEG1000 (26)
Compound 3 (0.099 g, 0.3 mmol), DMAP (0.004 g, 0.03 mmol) and coupling agent DCC (0.075
g, 0.4 mmol) were stirred in DCM (7 mL) for 30 min. Then, PEG (0.150 g, 0.15 mmol) was added.
After 16 h, DCM (10 mL) and acetic acid solution (0.25 M, 10 mL) were added to the reaction mixture.
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After 1 h the organic phase was separated and washed with deionized water (2 × 10 mL), dried over
anhydrous sodium sulfate, filtered, evaporated and purified by silica gel column chromatography
using chloroform/methanol 9:1, affording 26 (0.170 g, 74%) as a yellow wax. FT-IR (NaCl) v̄max: 3259
(s, ≡C-H w), 3008 (s, C-H w), 2929 (s, C-H w), 1733 (s), 1701 (s, O-C=O st) cm−1; 1H NMR (400 MHz,
CDCl3) δ: 7.47 (d, J = 8.9 Hz, 2H, H-5), 6.98 (d, J = 8.9 Hz, 2H, H-6), 4.82 (d, J = 2.2 Hz, 4H, H-1’), 4.23
(t, J = 4.6 Hz, 4H, H-16), 3.66 (s, 82H, CH2-PEG), 2.98 (t, J = 7.6 Hz, 4H, H-13), 2.66 (t, J = 7.6 Hz, 4H,
H-14), 2.57 (t, J = 2.0 Hz, 2H, H-3’), 2.45 (s, 3H, H-12), 2.34 (s, 3H, H-11); 13C NMR (101 MHz, CDCl3)
δ: 172.9 (C-15), 161.7 (C-2), 157.4(C-7), 151.4 (C-9), 147.5 (C-4), 122.5 (C-5), 121.7 (C-3), 115.0 (C-10),
114.7(C-8), 108.3 (C-6), 78.2 (C-2’), 77.3 (C-3’), 70.6 (CH2-PEG), 63.7 (C-16), 56.4 (C-1’), 32.6 (C-14), 23.1




Compound 26 (0.060 g, 0.04 mmol), DIPEA (0.2 mL, mmol), copper iodide (0.008 g, cat.) and
compound 16 (0.499 g, 1.3 mmol) were stirred in THF (4.0 mL) for 3 h. After solvent evaporation the
mixture was dissolved in dichloromethane and purified by column chromatography using hexane/ethyl
acetate (1:1) as eluent, affording 27 (0.070 g, 87%) as a yellow wax. 1H-NMR (CDCl3, 400 MHz) δ: 7.77
(d, J = 9.6 Hz, 2H, H-5’), 7.41 (d, J = 8.8 Hz, 2H, H-5), 7.30 (s, 2H, H-6”), 6.98 (d, J = 8.7 Hz, 2H, H-6),
6.24 (t, J = 6.8 Hz, 2H, H-1”), 4.70 (dd, J = 15.2, 10.0 Hz, 4H, H-6’), 4.47 (m, 2H, H-3”), 4.20 (t, J = 5.1 Hz,
4H, H-16,), 4.02 (q, J = 3.9 Hz, 2H, H-4”), 3.60 (s, J = 12.8 Hz, 100H, H-PEG, 5”), 2.95 (t, J = 7,1 Hz, 4H,
H-13), 2.62 (t, J = 7.0 Hz, 4H, H-14), 2.40–2.25 (m, 16H, H-11,12, 2”), 1.92–1.86 (m, 6H, H-8”); 13C-NMR
(CDCl3, 100 MHz) δ: 172.9 (C-15), 163.8 (C-9”), 161.9 (C-2), 158.1 (C-7), 151,3 (C-9), 150.4 (C-10”), 147.9
(C-4), 143.8 (C-4’), 135.5 (C-5’), 124.8 (C-6”), 122.8 (C-6), 121.3 (C-3), 114.7 (C-10), 114.1 (C-8), 111.4
(C-7”), 108.3 (C-5), 84.9 (C-1”), 84.5 (C-4”), 71.5 (C-3”), 71.2 (C-3”), 70.5 (C-PEG), 63.7 (C-16), 52.3 (C-5”),
51.3 (C-6’), 40.2 (C-2”), 32.6 (C-14), 23.1 (C-13), 15.0 (C-12), 12.6 (C-8”), 12.4 (C-8”), 8.3 (C-11).
3.3.28. 1-[1’-Ethylamide-Triazolyl-4]-1-O-Methyl-D-Glucopyranoside-PLGA Conjugate (28)
Compound 14 (0.006 g, 0.02 mmol) was dissolved in 4 mL of DMF, and commercially available
polymer poly(d,l-lactide-co-glycolide) (0.200 g, 0.02 mmol) was added. To the stirred reaction mixture,
methanesulfonic acid (0.5 mL, 7.70 mmol) was added and the reaction proceeded overnight at 65 ◦C.
The solution was cooled down, and 4 mL of cold water was added. The precipitated polymer was
collected by filtration to give the PLGA derivative 28 (0.193 g, 100%) as a white solid.
3.3.29. 7-((1-(2-Amide-Ethyl)-1H-1,2,3-Triazol-4-yl)methoxy)-4-Methyl-2H-Chromen-2-One-PLGA
Conjugate (29)
Compound 8 (0.006 g, 0.02 mmol) was dissolved in 4 mL of DMF, and poly(d,l-lactide-co-glycolide)
(0.200 g, 0.02 mmol) was added and this mixture stirred at room temperature. Methanesulfonic acid
(0.5 mL, 7.70 mmol) was added, and heated overnight at 65 ◦C. The solution was cooled and 4 mL
of cold water was added. The precipitated polymer was collected by filtration to give the PLGA
derivative 29 (0.197 g, 100%) as a white solid.
4. Conclusions
The use of these two polymeric building blocks (PEG and PLGA) has allowed us to prepare a new
type of macromolecule functionalized with carbohydrate and coumarin moieties. The polymer PEG was
selectively functionalized making possible the production of asymmetric macromolecules that contain
at one terminal the carbohydrate unit and at the other the coumarin molecule. This asymmetry provides
the ability to obtain a self-assembling control during the nanoparticles oil in water transformation.
This kind of macromolecules showed a tendency to form aggregates with sizes ranging between 220
and 580 nm, respectively, but the majority of the sample presented a polymeric film after the medium
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evaporation. This film formation can suggest that the hydrophobic core is not big enough to provide
the desired self-assembling effect.
PLGA has been successfully functionalized and transformed into stable and spherical nanoparticles
with a smooth surface, with practically no aggregation. The size of these different particles ranges
between 114–289 nm with a zeta potential value of −28.2 mV for the glucoconjugate and −56.0 mV for
the coumarin-containing derivative. Using a single oil in water emulsion technique, it was possible to
obtain low polydispersity indexes for all PLGA nanoparticles.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/25/7/1744/s1,
Figures S1–S51: 1H, 13C and MS/MALDI spectra of synthesized compounds.
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